Study of an Oral Fluid Testing Approach

Purpose

The purpose of this study is to identify and evaluate oral fluid testing as a biologic measure of cannabis use days that can be assessed remotely. The researchers will conduct this fully virtual study among a community sample of 200 individuals aged 18-30 years who have used cannabis at least 1 time per week on average in the past 30 days. Participants will complete oral fluid (saliva) tests, urine tests, and Timeline Follow-back interviews (self-report) that indicate their recent cannabis use (delta-9-THC). Participants will present for 3 virtual study visits across ~ 3-4 weeks and be asked to complete activities in between: Study Visit 1 (Day 0; informed consent, baseline survey, TLFB interview), Study Visit 2 (~ Day 7; TLFB interview, urine testing), 6 days of at-home videorecorded oral fluid testing, Study Visit 3 (~ Day 21; TLFB interview, urine test, oral fluid test, survey, interview). Individuals age 18-30 are invited to screen here: https://redcap.link/softa-bch

Conditions

  • Cannabis Use
  • Cannabis Intoxication
  • Cannabis Use Disorder

Eligibility

Eligible Ages
Between 18 Years and 30 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age 18 to 30 years - Cannabis use on >=1x/week in the past 30 days - Ownership of a portable device that is capable of videoconference and videorecording (i.e., smartphone, tablet computer, or laptop computer) - Ability to read and speak English - Availability for duration of the study (3-4 weeks). - To proceed to oral fluid testing, positive result for urinary TCH-COOH

Exclusion Criteria

• Inability/unwillingness to provide contact information Individuals age 18-30 are invited to screen here: https://redcap.link/softa-bch

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Prospective community sample Community sample of 200 younger adults aged 18-30 years who have used cannabis in the past 30 days, report use frequency of ≥1x/week, and have a positive test for urinary 11-nor-9-carboxy-delta-9-tetrocannabinol (THC-COOH) at baseline
  • Other: Biologic testing for THC
    Participants will be asked to complete at-home urine test(s) and a series of oral fluid tests.

Recruiting Locations

Boston Children's Hospital
Boston, Massachusetts 02115
Contact:
Lydia A. Shrier, MD, MPH
617-355-8306
lydia.shrier@childrens.harvard.edu

More Details

Status
Recruiting
Sponsor
Boston Children's Hospital

Study Contact

Foday Nabbie
617-355-2525
softa@childrens.harvard.edu